Merck KG has such a lopsidedly favorable deal with IMCL on the marketing of Erbitux that I find it hard to see how Merck gains from paying a premium to acquire the company. JMHO, FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”